
Hoth Therapeutics (NASDAQ: HOTH) Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal […]